Mark D. Tyson II, MD, MPH, characterizes the clinical landscape for patients with BCG-unresponsive NMIBC, outlines the real-world barriers that make bladder-sparing approaches important despite cystectomy's guideline-preferred status, and describes the efficacy and durability benchmarks he applies when evaluating new bladder-preserving therapies.